Table 1.

Examples of NSCLC Vaccines Formulations with the Therapeutic Maneuvers Explored for Immune Potentiating.

Cancer Vaccine	Immune Potentiating Platform	Priming & Boosting or Others Strategies for Immune Potentiating	Evidences of Immunogenicity	Level of Evidence	Reference
MAGE-12 peptide –based vaccine	Montanide ISA 51	CTX	T cells secreting IFNg and CTL immune response	Phase II clinical trial	J. Immunology 2005
CIMAvax EGF	EGF/P64k chemically linked Montanide ISA 51 adjuvant	CTX 72 hours before first immunization. Single injection site/Vaccine after first line ChT Four induction doses/ Monthly re-immunizations	High antibodies titters correlate with lower EGF serum concentrations	Phase II clinical trial	JCO 2008
Racotumumab	Alum	Five induction doses at 2-week intervals and monthly re-immunizations	High IgM and IgG specific response against NeuGcGM3, able to react with lung carcinoma tissues sections. Preliminary data suggests a correlation between the induction of antibodies and increased survival times of vaccinated patients.	Clinical exploratory study	Frontiers in Oncology, 2012
Belagenpumatucel-L	TGF-β2 antisense gene modified irradiated allogeneic tumor-cell vaccine	intradermal injections of the vaccine every 4-8 weeks	Strong correlation between the achievement of a combination of cellular and humoral immune responses and a significant increase in overall survival in the subjects vaccinated	Phase II clinical trial	Clin Oncol 27:15s, 2009 (suppl; abstr 3013)